Mark Lemmon, PhD, FRS is the Alfred Gilman Professor of Pharmacology, Deputy Director of Yale Cancer Center, and Co-Director of Yale Cancer Biology Institute. He returned to Yale as the David A. Sackler Professor of Pharmacology in 2015 after 19 years on the faculty at the University of Pennsylvania’s Perelman School of Medicine. At Penn, he was the George W. Raiziss Professor of Biochemistry and Biophysics as well as Chair of the department and an Investigator at the Abramson Family Cancer Research Institute. Dr. Lemmon was elected as a Fellow of the Royal Society (the UK's national academy) in 2016, and has been honored with the Dorothy Crowfoot Hodgkin Award of the Protein Society and the Stanley N. Cohen Biomedical Research Award from the University of Pennsylvania. He is on the Editorial Advisory Boards of several journals, including Cell and Molecular Cell, and is Chair of the Editorial Board of the Biochemical Journal.
Dr. Lemmon’s research focuses on understanding the signaling networks controlled by receptor tyrosine kinase (RTK) growth factors that, when mutated, cause cancers and other diseases. His laboratory combines biochemical, structural, biophysical, and cellular approaches to investigate how these networks function, and also collaborates with clinical groups to apply the mechanistic lessons learned to inhibitor choice and combating development of resistance to targeted therapies in the clinic.